FDA to perform regulatory review of vosoritide for use in children with achondroplasia

Vosoritide is an investigational, once daily injection analogue of C-type Natriuretic Peptide (CNP). There are no licensed treatments for this condition currently. Data reviewed will come from a phase III study, coupled with phase II data with up to 5 years follow-up.

Source:

Biospace Inc.